Dallas Ronald H, Rains Jason K, Wilder Keith, Humphrey William, Cross Shane J, Ghafoor Saad, Brazelton de Cardenas Jessica N, Hayden Randall T, Hijano Diego R
Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN 38105, USA.
Department of Critical Care and Pulmonary Medicine, St. Jude Children Research Hospital, Memphis, TN 38105, USA.
Pharmaceutics. 2020 Nov 29;12(12):1163. doi: 10.3390/pharmaceutics12121163.
Respiratory syncytial virus (RSV) is associated with adverse outcomes among immunocompromised patients. Inhaled ribavirin has been shown to improve mortality rates. The Small-Particle Aerosol Generator delivery system (SPAG-2) is the only FDA-cleared device to deliver inhaled ribavirin. However, it is difficult to set up and maintain. We developed a method for delivery of this medication using the vibrating mesh nebulizer (Aerogen). We did not observe any adverse events with this method.
呼吸道合胞病毒(RSV)与免疫功能低下患者的不良预后相关。吸入用利巴韦林已被证明可提高死亡率。小颗粒气溶胶发生器输送系统(SPAG-2)是唯一获得美国食品药品监督管理局(FDA)批准用于输送吸入用利巴韦林的设备。然而,它难以设置和维护。我们开发了一种使用振动网式雾化器(Aerogen)输送这种药物的方法。我们用这种方法未观察到任何不良事件。